Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Harrow (Nasdaq: HROW) will announce its third-quarter financial results for the period ending September 30, 2022, on November 14, 2022, after market close. A conference call will follow at 4:45 p.m. Eastern Time to discuss the results and company updates. Investors can access related materials through Harrow's website. The company is dedicated to developing innovative, affordable ophthalmic therapies.
Melt Pharmaceuticals has successfully dosed the last patient in its Phase 2 pivotal study for MELT-300, a novel sublingual formulation for procedural sedation in cataract surgery. Over 330 subjects participated in this randomized, double-blind study, comparing MELT-300 against placebo and individual components. Top-line results are expected by year-end, marking a critical advancement in providing opioid-free sedation. If successful, Melt plans to engage with the FDA regarding the next steps for MELT-300.
Harrow (Nasdaq: HROW) has announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, part of Revelation Pharma Corporation. This strategic move aligns with Harrow's goal to focus exclusively on ophthalmic therapies. The sale encompasses various assets, excluding a production facility, while Revelation will hire Harrow employees involved in this area. The transition support from Harrow will last approximately three months. This decision aims to enhance Harrow's core competencies as it approaches multiple significant milestones, including upcoming product launches.
ImprimisRx, America’s leading Ophthalmic Pharmacy™, has launched Fortisite™, a compounded topical antibiotic formulated with Tobramycin 1.5% and Vancomycin 5%. This unique formulation is stable at refrigerated temperatures for up to 180 days and aims to meet unmet clinical needs. Available through the ImprimisRx 503A pharmacy now, it will soon be accessible via the FDA-registered 503B outsourcing facility. A Patient Access Program and a 100% replacement guarantee for expired products further enhance accessibility for eyecare professionals.
IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) has received FDA approval, marking the first branded ocular anesthetic in the U.S. in nearly 14 years. Licensed by Harrow from Sintetica, IHEEZO is designed for ocular surface anesthesia and boasts a patent protecting it until 2038. Its clinical studies showed rapid action and effective anesthesia for cataract surgeries, without the need for supplemental treatments. With an estimated 4.5 million cataract surgeries annually in the U.S., Harrow aims for an accelerated commercial launch, enhancing its market presence in the ophthalmic sector.
Harrow Health, Inc. (Nasdaq: HROW), a pharmaceutical company specializing in eyecare, announced participation in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022. CEO Mark L. Baum and CFO Andrew Boll will represent the company. A pre-recorded presentation will be available on Harrow's investor relations webpage starting at 7:00 a.m. ET on that date and archived for 90 days. Additionally, management will engage in one-on-one meetings during the conference, which interested investors can request through H.C. Wainwright.
Harrow Health, Inc. (NASDAQ: HROW) reported record revenues of $23.3 million for Q2 2022, a 29% increase from $18.1 million the previous year. The gross profit also hit a record at $16.8 million, a 22% rise from $13.7 million year-over-year. The company shipped 718,000 product units, which is a 4% year-over-year increase. However, Harrow reported a net loss of $6.2 million compared to $3 million last year. Cash and cash equivalents stood at $46.4 million as of June 30, 2022, as the company looks forward to key events in the second half of the year.
Harrow Health, Inc. (Nasdaq: HROW) will release its financial results for Q2 ended
Harrow Health, Inc. (NASDAQ: HROW) has successfully transferred the New Drug Applications (NDAs) for three FDA-approved ophthalmic medicines: IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Both IOPIDINE 1% and MAXITROL are now commercially available, with MOXEZA set for later release. This move follows their acquisition of these products in December 2021, during which Harrow began receiving net profits from sales. CEO Mark L. Baum expressed optimism about market interest and plans for commercial strategies targeting healthcare professionals and payers.
Harrow Health (NASDAQ: HROW) reported a record revenue of $22.1 million for Q1 2022, marking a 43% increase from $15.4 million in Q1 2021. The gross profit reached $16.2 million, up 38% year-over-year. A total of 689,000 product units were shipped, a 72% increase from the prior year. Despite a net loss of $2.4 million, the company anticipates a strong year driven by organic growth and plans for AMP-100's FDA review on October 16, 2022. Cash and equivalents stood at $42 million as of March 31, 2022.